About TOGA

Our Impact

TOGA is dedicated to lung cancer research, prevention, and improved patient outcomes in Australia and New Zealand. Explore our research achievements, including empowering healthcare professionals, and contributing to a projected decrease in lung cancer deaths.

How We Create Change

Our leading priority is to design and conduct clinical trials. 

Progress in healthcare is only made by investing in research. Research provides sound evidence upon which practitioners can base treatment decisions in future patients. 

TOGA research has provided a transformative journey for Australians diagnosed with non-small cell lung cancer (NSCLC). 

The ASPiRATION program was a pioneering partnership between government, industry, and academia. The study was led by TOGA, in collaboration with Omico (Australian Genomic Cancer Medicine Centre) and the University of Sydney NHMRC Clinical Trials Centre (CTC). 

ASPiRATION ensured equitable access to tests capable of identifying life-saving treatments for patients with rare forms of NSCLC. Several participants were able to access targeted therapies through clinical trials.

As well as a major advancement in research, the ASPiRATION study contributed to the feasibility of the MSAC item number for NGS in non-squamous NSCLC. Lung cancer is the first cancer to have genomic testing reimbursed by Medicare.

TOGA members advocate for innovative therapies and spearhead clinical trials for emerging drugs.

Their relentless efforts aim to improve NSCLC patient outcomes.
ASPiRATION study completes recruitment.

Routine testing for all NSCLC patients becomes standard.
TOGA introduces the ASPiRATION cohort study, transforming Australian NSCLC care.

1,000 Stage 4 MSCLC patients across the country to undergo crucial mutation testing.

Those with relevant mutations gain access to targeted therapies.
Routine testing and reimbursement of some newer targeted therapies lag, limiting patient access.

TOGA conducts smaller clinical trials that provide testing and access to these newer therapies for some patients.
Introduction of therapies targeted to mutations extends life for Stage 4 NSCLC patients, sometimes up to 17+ years.
Discoveries in NSCLC research unveil specific mutations driving tumour growth.
Ongoing
2023
2021
2016
2005
2004
RESEARCH CONCEPTS ENDORSED
0
CLINICAL TRIAL SUPPORTED
0
INSPIRATIONAL RESEARCH GRANTS
0

Inspirational Research Grant

While lung cancer remains the deadliest cancer, less than 6% of research funding goes towards thoracic cancers. To bridge this gap, TOGA’s Inspirational Research Grant creates more opportunities for tumor-specific funding and successful clinical trials. 

TOGA’s Inspirational Research Grant has been created from philanthropic donations and has supported 8 research projects since its inception. 

From microbiome research to resistance to immunotherapy, the Inspirational Research Grant has awarded grants to deserving and high-quality research projects. 

While these grants are small, it paves the way to something bigger hoping to give lung cancer and mesothelioma patients access to life-saving treatments and world-class care.

As the leading authority in Australia and New Zealand for the study of thoracic cancers, the Thoracic Oncology Group Australias represents the full range of professional disciplines involved in caring for patients with thoracic cancer and is dedicated to discovering better ways to diagnose, treat and support people with thoracic cancer. TOGA works collaboratively across Australia and New Zealand to inform best practice care and treatment, all with the aim to prevent and ultimately find a cure for thoracic cancer.